Xeris Biopharma Holdings (XERS) Consolidated Net Income (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Consolidated Net Income came in at $2.2 million in Q1 2026, up 124.23% YoY from $996298.7 in Q1 2025, and down 79.84% on a QoQ basis from $11.1 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Consolidated Net Income (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Consolidated Net Income data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Consolidated Net Income rose 124.23% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 126.64% YoY) and the FY2025 annual result came in at $554000.0, up 101.01% from the prior year.
- Consolidated Net Income declined to $2.2 million in Q1 2026, from $11.1 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $11.1 million in Q4 2025 to a low of -$33.7 million in Q1 2022.
- A 5-year average of -$12.3 million and a median of -$13.4 million in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 83.12% — and 2025, when it surged 316.72%.
- Tracing XERS's Consolidated Net Income over 5 years: stood at -$12.9 million in 2022, then decreased by 3.56% to -$13.4 million in 2023, then soared by 61.81% to -$5.1 million in 2024, then surged by 316.72% to $11.1 million in 2025, then tumbled by 79.84% to $2.2 million in 2026.
- The last three Consolidated Net Income figures came in at $2.2 million (Q1 2026), $11.1 million (Q4 2025), and $621000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | -31.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.10 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 11.08 Mn |
| Sep 30, 2025 | 621,000.00 |
| Jun 30, 2025 | -1.93 Mn |
| Mar 31, 2025 | -9.22 Mn |
| Dec 31, 2024 | -5.11 Mn |
| Sep 30, 2024 | -15.74 Mn |
| Jun 30, 2024 | -15.01 Mn |
| Mar 31, 2024 | -18.98 Mn |
| Dec 31, 2023 | -13.39 Mn |
| Sep 30, 2023 | -12.19 Mn |
| Jun 30, 2023 | -19.84 Mn |
| Mar 31, 2023 | -16.83 Mn |
| Dec 31, 2022 | -12.93 Mn |
| Sep 30, 2022 | -21.83 Mn |
| Jun 30, 2022 | -26.19 Mn |
| Mar 31, 2022 | -33.71 Mn |
| Dec 31, 2021 | -50.79 Mn |
| Sep 30, 2021 | -26.01 Mn |